Ginkgo Bioworks Holdings, Inc. WT Price & Performance (DNA-WT)

The FDA’s decision to end mandatory animal testing for new drug approvals has driven significant gains for AI-enabled biotech firms. Recursion Pharmaceuticals, Ginkgo Bioworks, Absci Corp., and Schrodinger all posted double-digit rallies following the announcement, as the agency pivots to human-relevant, technology-driven testing methods.12

Eli Lilly shares climbed sharply after announcing successful phase 3 results for its oral diabetes and weight-loss candidate, orforglipron. The pharmaceutical sector also saw Spruce Bio rebound through a licensing deal, while industry groups warned that new tariffs could threaten biosimilar discounts and future sector stability.34

Ginkgo Bioworks’ share price has risen over 7% in the past week, with a current average one-year price target of $8.77. Despite recent gains, analyst opinions remain mixed, and short interest is high, signaling ongoing uncertainty and volatility for the synthetic biology company.25